A phase III study of HS-410 either as an adjunct to BCG or a replacement for BCG altogether in patients with non-muscle invasive bladder cancer

Trial Profile

A phase III study of HS-410 either as an adjunct to BCG or a replacement for BCG altogether in patients with non-muscle invasive bladder cancer

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 11 May 2017

At a glance

  • Drugs Vesigenurtucel-L (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 May 2017 Status changed from planning to withdrawn prior to enrolment, as reported in a Heat Biologics media release.
    • 15 Aug 2016 According to Heat Biologics media release, the company anticipates to reported topline data from this study in the fourth quarter of 2016.
    • 13 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top